ADOCIA Announces Changes in its Board of Directors with the Appointment of a New Director and a Board Observer

• Ekaterina Smirnyagina steps down from the Board of Directors after thirteen years of service
• Maureen Deehan co-opted as Director
• Suman Shirodkar appointed as Board Observer

LYON, France--(BUSINESS WIRE)--Regulatory News:

Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced changes to the composition of its Board of Directors, decided at the Board meeting held on August 18, 2026.

Ekaterina Smirnyagina has stepped down from her position as Director after thirteen years of service, in consultation with the Board of Directors. The Board of Directors has co-opted Maureen Deehan as an independent Director. Her co-optation as Director will be submitted for shareholders’ approval at the next Annual shareholders’ meeting of Adocia.

In addition, Suman Shirodkar, M.B., B.S., Ph.D., has been appointed as Board Observer. Her candidacy as Director will be submitted at the next Annual shareholders’ meeting of Adocia.

The Board of Directors now comprises six Directors (four men and two women), including five independent members, and one Board Observer.

“On behalf of the Board of Directors and the entire team, we would like to thank Ekaterina for her valuable contribution and commitment to Adocia over the past 13 years. We are delighted to welcome Maureen Deehan and Suman Shirodkar, who will strengthen our Board with their exceptional experience in business development, clinical and regulatory strategy, and, more broadly, corporate strategy,” said Stéphane Boissel, Chairman, and Olivier Soula, CEO and Co-founder.

“It is an honor for me to join Adocia’s Board of Directors. Its diversified portfolio of specialty products addresses important challenges in the treatment of diabetes and obesity. I look forward to supporting the team in pursuing partnership opportunities,” commented Maureen Deehan, Director of the Company’s Board of Directors.

“I am delighted to contribute to the Board of Directors and to help shape the Company’s strategy with a view to maximizing value creation,” added Suman Shirodkar, Board Observer of the Company’s Board of Directors.

About Maureen Deehan, Ph.D.

Dr. Deehan is a qualified biotechnology and pharmaceutical professional with 25 years of drug development and commercialization experience. Since March 2025, she has been an independent Director at TregShield Bio., a US based company with a tissue-selective, antibody platform, for the treatment of inflammatory and infectious diseases. Dr Deehan obtained her PhD from the Faculty of Medicine at Glasgow University, and subsequently spent 8 years in academic research before moving into industry. She has gained expertise in all stages of the drug development cycle, across a broad range of therapeutic areas and her last 11 years have been spent in global corporate development and C-suite roles at Novimmune SA, Nordic Nanovector ASA and Vivtex Corporation. In May 2024, as the CEO of Vivtex Corporation, she was awarded the Elizabeth Elting award for the most promising female CEO of a US Life Sciences, start-up company. She has gained a successful track record in business development and deal-making, for product and technology platform transactions, with a range of companies including a recent $2.1 billion partnership with Novo Nordisk for oral obesity drugs.

About Suman Shirodkar, M.B., B.S., Ph.D.

Dr. Shirodkar is a physician-scientist and executive with over 25 years of experience in product development, business development, commercialization and general management in the pharmaceutical and biotech industries. She held senior roles at McKinsey and Co, Pfizer, Novartis and the Medicines Company with experience across early portfolio strategy, late-stage product development and approval, and global commercialization. She became the CEO of Cambridge Epigenetix (now Biomodal) and also served as the CEO and Co-Founder of Larkspur Biosciences. Additionally, she serves on the Boards and is a strategic advisor to several biotech companies, including NanoPhoria, which recently closed a €83.5 million Series A financing. She also serves as a Trustee & Board Member for Prostate Cancer Research U.K. and U.S. Suman holds a medical degree (M.B., B.S.) from the University of Bombay and a Ph.D. from Harvard University.

About Adocia

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.

The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone^® for the stabilization and enhancement of peptide formulations and combinations; 2) AdoXLong^™, a long-acting peptide platform; 3) AdOral^®, an oral peptide delivery technology; and 4) AdoShell^®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation.

Adocia holds more than 25 patent families. Based in Lyon, the Company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).

Disclaimer

This press release contains certain forward-looking statements concerning Adocia, its business and the markets in which Adocia operates. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those set forth in the “Risk Factors” section of the universal registration document that was filed with the French Autorité des marchés financiers on April 29, 2026, available for free on Adocia’s website (www.adocia.com). Those risks include in particular uncertainties inherent in Adocia's short- or medium-term working capital requirements, in research and development, future clinical data, analyses and the evolution of economic conditions, the financial markets and the markets in which Adocia operates, which could impact the Company's short-term financing requirements and its ability to raise additional funds.

The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia at this time. The occurrence of all or part of such risks could cause the actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or a solicitation of an offer to buy or subscribe for, Adocia shares in any country.